In this medfyle

Imetelstat, a first-in-class telomerase inhibitor, has been approved for patients with LR-MDS who are dependent on red blood cell transfusions and have failed or are ineligible for ESAs. Imetelstat uniquely inhibits malignant stem and progenitor cells, demonstrating meaningful and durable transfusion independence and significant hemoglobin improvement. Its approval signals a critical advancement in addressing the unmet needs of this challenging patient population, offering a promising new option for those with limited treatment options.